Effects of acute and chronic quercetin administration on methylphenidate-induced hyperlocomotion and oxidative stress

Life Sciences

Volumn 171, Issue , 2017, Pages 1-8

  Kanazawa, Luiz K S ^a   Vecchia, Débora D ^a   Wendler, Etiéli M ^a   Hocayen, Palloma de A S ^a   Beirão, Paulo S ^a   de Mélo, Manuela L ^a   dos Reis Lívero, Francislaine A ^a   Corso, Claudia Rita ^a   Stipp, Maria Carolina ^a   Acco, Alexandra ^a   Andreatini, Roberto ^a  

^a FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

Author keywords

Bipolar disorder; Hyperlocomotion; Mania; Oxidative stress; Protein kinase C; Quercetin

Indexed keywords

DIAZEPAM; GLUTATHIONE; LITHIUM; METHYLPHENIDATE; PROTEIN KINASE C; QUERCETIN;

ACUTE DRUG ADMINISTRATION; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; CORPUS STRIATUM; DRUG EFFECT; EXPERIMENTAL HYPERACTIVITY; HIPPOCAMPUS; LIPID PEROXIDATION; MALE; MOUSE; NONHUMAN; OXIDATIVE STRESS; PREFRONTAL CORTEX; ANIMAL; ANIMAL BEHAVIOR; BRAIN; DOSE RESPONSE; DRUG EFFECTS; LOCOMOTION;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; DOSE-RESPONSE RELATIONSHIP, DRUG; LOCOMOTION; MALE; METHYLPHENIDATE; MICE; OXIDATIVE STRESS; QUERCETIN;

EID: 85010189033     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2017.01.007     Document Type: Article

References (57)

1. [1] Nivoli, A.M.A., Murru, A., Goikolea, J.M., Crespo, J.M., Montes, J.M., González-Pinto, A., García-Portilla, P., Bobes, J., Sáiz-Ruiz, J., Vieta, E., New treatment guidelines for acute bipolar mania: a critical review. J. Affect. Disord. 140:2 (2012), 125–141.
2. [2] Hoertel, N., de Maricourt, P., Gorwood, P., Novel routes to bipolar disorder drug discovery. Expert Opin. Drug Discovery 8:8 (2013), 907–918.
3. [3] Andreazza, A.C., Kauer-Sant'anna, M., Frey, B.N., Bond, D.J., Kapczkinski, F., Young, L.T., Yatham, L.N., Oxidative stress markers in bipolar disorder: a meta-analysis. J. Affect. Disord. 111:2–3 (2008), 135–144.
4. [4] Berk, M., Kapczinski, F., Andreazza, A.C., Dean, O.M., Giorlando, F., Maes, M., Yücel, M., Gama, C.S., Dodd, S., Dean, B., Magalhães, P.V.S., Amminger, P., McGorry, P., Malhi, G.S., Pathways underlying neuroprogression in bipolar disorder: focus on inflammation, oxidative stress and neurotrophic factors. Neurosci. Biobehav. Rev. 35:3 (2011), 804–817.
5. [5] Manji, H.K., Lenox, R.H., Signaling: cellular insights into the pathophysiology of bipolar disorder. Biol. Psychiatry 48 (2000), 518–530.
6. [6] Armani, F., Andersen, M.L., Galduróz, J.C., Tamoxifen use for the management of mania: a review of current preclinical evidence. Psychopharmacology 231:4 (2014), 639–649.
7. [7] Frey, B.N., Valvassori, S.S., Réus, G.Z., Martins, M.R., Petronilho, F.C., Bardini, K., Dal-Pizzol, F., Kapczinski, F., Quevedo, J., Effects of lithium and valproate on amphetamine-induced oxidative stress generation in an animal model of mania. J. Psychiatry Neurosci. 31:5 (2006), 326–332.
8. [8] Wang, H.Y., Friedman, E., Lithium inhibition of protein kinase C activation-induced serotonin release. Psychopharmacology 99:2 (1989), 213–218.
9. [9] Macêdo, D.S., Medeiros, C.D., Cordeiro, R.C., Sousa, F.C., Santos, J.V., Morais, T.A., Hyphantis, T.N., McIntyre, R.S., Quevedo, J., Carvalho, A.F., Effects of alpha-lipoic acid in an animal model of mania induced by D-amphetamine. Bipolar Disord. 14:7 (2012), 707–718.
10. [10] Abrial, E., Bétourné, A., Etiévant, A., Lucas, G., Scarna, H., Lambás-Señas, L., Haddjeri, N., Protein kinase C inhibition rescues manic-like behaviors and hippocampal cell proliferation deficits in the sleep deprivation model of mania. Int. J. Neuropsychopharmacol., 18(2), 2015 pii: pyu031,.
11. [11] Young, J.W., Henry, B.L., Geyer, M.A., Predictive animal models of mania: hits, misses and future directions. Br. J. Pharmacol. 164:4 (2011), 1263–1284.
12. [12] Mines, M.A., Beurel, E., Jope, R.S., Examination of methylphenidate-mediated behavior regulation by glycogen synthase kinase-3 in mice. Eur. J. Pharmacol. 698:1–3 (2013), 252–258.
13. [13] Pereira, M., Martynhak, B.J., Baretta, I.P., Correia, D., Siba, I.P., Andreatini, R., Antimanic-like effect of tamoxifen is not reproduced by acute or chronic administration of medroxyprogesterone or clomiphene. Neurosci. Lett. 500:2 (2011), 95–98.
14. [14] Barbosa, F.J., Hesse, B., de Almeida, R.B., Baretta, I.P., Boerngen-Lacerda, R., Andreatini, R., Magnesium sulfate and sodium valproate block methylphenidate-induced hyperlocomotion, an animal model of mania. Pharmacol. Rep. 63:1 (2011), 64–70.
15. [15] Tonelli, D.A., Pereira, M., Siba, I.P., Martynhak, B.J., Correia, D., Casarotto, P.C., Biojone, P.C., Guimarães, F.S., Joca, S.L., Andreatini, R., The antimanic-like effect of phenytoin and carbamazepine on methylphenidate-induced hyperlocomotion: role of voltage-gated sodium channels. Fundam. Clin. Pharmacol. 27:6 (2013), 650–655.
16. [16] Arunagiri, P., Rajeshwaran, K., Shanthakumar, J., Tamilselvan, T., Balamurugan, E., Combination of omega-3 fatty acids, lithium, and aripiprazole reduces oxidative stress in brain of mice with mania. Biol. Trace Elem. Res. 160:3 (2014), 409–417.
17. [17] Nogoceke, F.P., Barcaro, I.M., de Sousa, D.P., Andreatini, R., Antimanic-like effects of (R)-(−)-carvone and (S)-(+)-carvone in mice. Neurosci. Lett. 619 (2016), 43–48.
18. [18] Souza, L.S., Silva, E.F., Santos, W.B., Asth, L., Lobão-Soares, B., Soares-Rachetti, V.P., Medeiros, I.U., Gavioli, E.C., Lithium and valproate prevent methylphenidate-induced mania-like behaviors in the hole board test. Neurosci. Lett. 629 (2016), 143–148.
19. [19] Dajas, F., Abin-Carriquiry, J.A., Arredondo, F., Blasina, F., Echeverry, C., Martínez, M., Rivera, F., Vaamonde, L., Quercetin in brain diseases: potential and limits. Neurochem. Int. 89 (2015), 140–148.
20. [20] Gamet-Payrastre, L., Manenti, S., Gratacap, M.P., Tulliez, J., Chap, H., Payrastre, B., Flavonoids and the inhibition of PKC and PI 3-kinase. Gen. Pharmacol. 32:3 (1999), 279–286.
21. [21] Kanazawa, L.K., Vecchia, D.D., Wendler, E.M., Hocayen, P.A., Dos Reis Lívero, F.A., Stipp, M.C., Barcaro, I.M., Acco, A., Andreatini, R., Quercetin reduces manic-like behavior and brain oxidative stress induced by paradoxical sleep deprivation in mice. Free Radic. Biol. Med. 99 (2016), 79–86.
22. [22] Boots, A.W., Drent, M., de Boer, V.C., Bast, A., Haenen, G.R., Quercetin reduces markers of oxidative stress and inflammation in sarcoidosis. Clin. Nutr. 30:4 (2011), 506–512.
23. [23] Bhutada, P., Mundhada, Y., Bansod, K., Ubgade, A., Quazi, M., Umathe, S., Mundhada, D., Reversal by quercetin of corticotrophin releasing factor induced anxiety- and depression-like effect in mice. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 34:6 (2010), 955–960.
24. [24] Sabioni, P., Baretta, I.P., Ninomiya, E.M., Gustafson, L., Rodrigues, A.L., Andreatini, R., The antimanic-like effect of tamoxifen: behavioral comparison with other PKC-inhibiting and antiestrogenic drugs. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 32:8 (2008), 1927–1931.
25. [25] Gould, T.J., Keith, R.A., Bhat, R.V., Differential sensitivity to lithium's reversal of amphetamine-induced open-field activity in two inbred strains of mice. Behav. Brain Res. 118:1 (2001), 95–105.
26. [26] Sedlak, J., Lindsay, R.H., Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal. Biochem. 25:1 (1968), 192–205.
27. [27] Jiang, Z.Y., Hunt, J.V., Wolff, S.P., Ferrous ion oxidation in the presence of xylenol orange for detection of lipid hydroperoxide in low density lipoprotein. Anal. Biochem. 202:2 (1992), 384–389.
28. [28] Einat, H., Modelling facets of mania: new directions related to the notion of endophenotypes. J. Psychopharmacol. 20:5 (2006), 714–722.
29. [29] Machado-Vieira, R., Kapczinski, F., Soares, J.C., Perspectives for the development of animal models of bipolar disorder. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28:2 (2004), 209–224.
30. [30] Huey, L.Y., Janowsky, D.S., Judd, L.L., Abrams, A., Parker, D., Clopton, P., Effects of lithium carbonate on methylphenidate-induced mood, behavior, and cognitive processes. Psychopharmacology 73:2 (1981), 161–164.
31. [31] Cousins, D.A., Butts, K., Young, A.H., The role of dopamine in bipolar disorder. Bipolar Disord. 11:8 (2009), 787–806.
32. [32] Post, R.M., Jimerson, D.C., Bunney, W.E. Jr., Goodwin, F.K., Dopamine and mania: behavioural and biochemical effects of the dopamine receptor blocker pimozide. Psychopharmacology 67:3 (1980), 297–305.
33. [33] Dziedzicka-Wasylewska, M., Mackowiak, M., Fijat, K., Wedzony, K., Adaptive changes in the rat dopaminergic transmission following repeated lithium administration. J. Neural Transm. 103:7 (1996), 765–776.
34. [34] Smith, R.C., Davis, J.M., Comparative effects of D-amphetamine, L-amphetamine, and methylphenidate on mood in man. Psychopharmacology 53:1 (1977), 1–12.
35. [35] Huey, L.Y., Janowsky, D.S., Judd, L.L., Abrams, A., Parker, D., Clopton, P., Effects of lithium carbonate on methylphenidate-induced mood, behavior, and cognitive processes. Psychopharmacology 73:2 (1981), 161–164.
36. [36] Chakraborty, K., Grover, S., Methylphenidate-induced mania-like symptoms. Indian J. Pharm. 43:1 (2011), 80–81.
37. [37] Ekinci, O., Direk, M.Ç., Ekinci, N., Okuyaz, C., Manic symptoms due to methylphenidate use in an adolescent with traumatic brain injury. Clinical Psychopharmacology and Neuroscience. 14:3 (2016), 314–317.
38. [38] Burrows, K.B., Gudelsky, G., Yamamoto, B.K., Rapid and transient inhibition of mitochondrial function following methamphetamine or 3,4-methylenedioxymethamphetamine administration. Eur. J. Pharmacol. 398:1 (2000), 11–18.
39. [39] Shanthakumar, J., Tamilselvan, T., Arunagiri, P., Rajeshwaran, K., Balamurugan, E., Role of caffeine in lithium treated methylphenidate induced oxidative stress in an animal model of mania. Asian Journal of Pharmaceutical Sciences. 3:4 (2013), 166–171.
40. [40] Wu, G., Fang, Y.Z., Yang, S., Lupton, J.R., Turner, N.D., Glutathione metabolism and its implications for health. J. Nutr. 134:3 (2004), 489–492.
41. [41] Gawryluk, J.W., Wang, J.F., Andreazza, A.C., Shao, L., Young, L.T., Decreased levels of glutathione, the major brain antioxidant, in post-mortem prefrontal cortex from patients with psychiatric disorders. Int. J. Neuropsychopharmacol. 14:1 (2011), 123–130.
42. [42] Macêdo, D.S., de Lucena, D.F., Queiroz, A.I.G., Cordeiro, R.C., Araújo, M.M., Sousa, F.C., Vasconcelos, S.M., Hyphantis, T.N., Quevedo, J., McIntyre, R.S., Carvalho, A.F., Effects of lithium on oxidative stress and behavioral alterations induced by lisdexamfetamine dimesylate: relevance as an animal model of mania. Prog. Neuro-Psychopharmacol. Biol. Psychiatry 43 (2013), 230–237.
43. [43] Jornada, L.K., Valvassori, S.S., Steckert, A.V., Moretti, M., Mina, F., Ferreira, C.L., Arent, C.O., Dal-Pizzol, F., Quevedo, J., Lithium and valproate modulate antioxidant enzymes and prevent ouabain-induced oxidative damage in an animal model of mania. J. Psychiatr. Res. 45:2 (2011), 162–168.
44. [44] Bhalla, P., Dhawan, D.K., Protective role of lithium in ameliorating the aluminium-induced oxidative stress and histological changes in rat brain. Cell. Mol. Neurobiol. 29:4 (2009), 513–521.
45. [45] Joshi, Y.B., Praticò, D., Lipid peroxidation in psychiatric illness: overview of clinical evidence. Oxidative Med. Cell. Longev., 828702, 2014, 2014.
46. [46] Cui, J., Shao, L., Young, L.T., Wang, J.F., Role of glutathione in neuroprotective effects of mood stabilizing drugs lithium and valproate. Neuroscience 144:4 (2007), 1447–1453.
47. [47] Andreazza, A.C., Cassini, C., Rosa, A.R., Leite, M.C., de Almeida, L.M., Nardin, P., Cunha, A.B., Ceresér, K.M., Santin, A., Gottfried, C., Salvador, M., Kapczinski, F., Gonçalves, C.A., Serum 100B and antioxidant enzymes in bipolar patients. Journal of Pyschiatric Research. 41:6 (2007), 523–529.
48. [48] Machado-Vieira, R., Andreazza, A.C., Viale, C.I., Zanatto, V., Ceresér, V. Jr., da Silva Vargas, R., Kapczinski, F., Portela, L.V., Souza, D.O., Salvador, M., Gentil, V., Oxidative stress parameters in unmedicated and treated bipolar subjects during initial manic episode: a possible role for lithium antioxidant effects. Neurosci. Lett. 421:1 (2007), 33–36.
49. [49] Martins, M.R., Reinke, A., Petronilho, F.C., Gomes, K.M., Dal-Pizzol, F., Quevedo, J., Methylphenidate treatment induces oxidative stress in young rat brain. Brain Res. 1078:1 (2006), 189–197.
50. [50] Pereira, M., Andreatini, R., Schwarting, R.K., Brenes, J.C., Amphetamine-induced appetitive 50-kHz calls in rats: a marker of affect in mania?. Psychopharmacology 231:13 (2014), 2567–2577.
51. [51] Andreatini, R., Pereira, M., Siba, I.P., Pizzolatti, M.G., Santos, A.R.S., Ruani, A.P., Myricitrin, a PKC inhibitor, exerts antimanic-like effects in animal models. Eur. Neuropsychopharmacol. 23:Suppl. 2 (2013), S357–S358.
52. [52] Friedman, E., Wang, H.Y., Levinson, D., Connell, T.A., Singh, H., Altered platelet protein kinase C activity in bipolar affective disorder, manic episode. Biol. Psychiatry 33:7 (1993), 520–525.
53. [53] Chen, R., Furman, C.A., Zhang, M., Kim, M.N., Gereau, R.W. 4th, Leitges, M., Gnegy, M.E., Protein kinase C beta is a critical regulator of dopamine transporter trafficking and regulates the behavioral response to amphetamine in mice. J. Pharmacol. Exp. Ther. 328:3 (2009), 912–920.
54. [54] Vaughan, R.A., Foster, J.D., Mechanisms of dopamine transporter regulation in normal and disease states. Trends Pharmacol. Sci. 34:9 (2013), 489–496.
55. [55] Mikelman, S., Mardirossian, N., Gnegy, M.E., Tamoxifen and amphetamine abuse: are there therapeutic possibilities?. J. Chem. Neuroanat., 2016 pii: S0891-0618(16)30071-0.
56. [56] Segura-Aguilla, J., Paris, I., Muñoz, P., Ferrari, E., Zecca, L., Zucca, F.A., Protective and toxic roles of dopamine in Parkinson's disease. J. Neurochem. 129:6 (2014), 898–915.
57. [57] Model, C.S., Gomes, L.M., Scaini, G., Ferreira, G.K., Gonçalves, C.L., Rezin, G.T., Steckert, A.V., Valvassori, S.S., Varela, R.B., Quevedo, J., Streck, E.L., Omega-3 fatty acids alter behavioral and oxidative stress parameters in animals subjected to fenproporex administration. Metab. Brain Dis. 29:1 (2014), 185–192.